Category: Latest News
-
Greenwich LifeSciences Shares Soar After FDA Grants Fast Track for Breast Cancer Therapy
Shares of Greenwich LifeSciences (NASDAQ:GLSI) jumped 26% in premarket trading on Wednesday following news that the company’s breast cancer therapy received an important regulatory milestone. The biotech firm said its GLSI-100 treatment earned “fast track” designation from the U.S. Food and Drug Administration (FDA). “This designation is designed to accelerate the development and review process…
-
PMV Pharmaceuticals Shares Jump After Positive Cancer Drug Trial Data
PMV Pharmaceuticals (NASDAQ:PMVP) stock surged 16% after the company released encouraging interim results from its Phase 2 PYNNACLE trial, evaluating rezatapopt in patients with various solid tumors carrying the TP53 Y220C mutation. The precision oncology study showed a 33% overall response rate among 97 evaluable patients across eight tumor types, with a median response duration…
-
Joby Aviation Shares Jump on Plan to Add Blade Flights to Uber App
Joby Aviation, Inc. (NYSE:JOBY) saw its stock climb 7.5% after announcing plans to integrate Blade’s air mobility services into the Uber app as early as next year. The move extends Joby’s strategic partnership with Uber Technologies, Inc. (NYSE:UBER) and comes on the heels of its recent acquisition of Blade’s passenger operations. Through the integration, Uber…
-
Avidity Shares Climb on Promising DMD44 Trial Results for Del-zota
Avidity Biosciences (NASDAQ:RNA) gained 2% on Wednesday after releasing fresh clinical data showing that its experimental therapy del-zota reversed disease progression in patients with Duchenne muscular dystrophy (DMD44). The San Diego-based biotech said that patients who received del-zota continuously for about one year in the EXPLORE44 and EXPLORE44-OLE studies experienced “unprecedented improvement” across several functional…
-
Chewy Stock Slides After Q2 Results Fall Short of Expectations
Chewy, Inc. (NYSE:CHWY) saw its shares sink more than 7% on Wednesday after reporting second-quarter earnings that came in line with Wall Street forecasts and a modest revenue beat, but failed to deliver the upside investors had been hoping for. The online pet retailer reported adjusted EPS of $0.33, matching analyst estimates, while revenue reached…
-
CAMP4 Therapeutics Shares Triple After Securing $100M Private Placement
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) saw its stock skyrocket 200% after announcing an oversubscribed private placement that could raise up to $100 million to support its lead program targeting SYNGAP1-related disorders. The biotech firm has already raised $50 million upfront through sales of common stock at $1.53 per share and pre-funded warrants. An additional $50 million…
-
NIO Stock Slides After Announcing 182 Million Share Sale
NIO Inc. (NYSE:NIO) shares tumbled 8.3% in premarket trading Wednesday after the Chinese EV manufacturer unveiled plans for a sizable equity raise. The Shanghai-based company said it will issue roughly 182 million Class A ordinary shares, with underwriters granted a 30-day option to purchase up to 27 million additional depositary receipts. NIO said it plans…
-
Amylyx Pharmaceuticals Stock Slips After Discounted $175M Share Sale
Amylyx Pharmaceuticals (NASDAQ:AMLX) saw its shares retreat more than 4% in premarket trading Wednesday following the announcement of a new equity raise. The Cambridge, Massachusetts-based biotech priced a follow-on offering of 17.5 million shares at $10 apiece, marking a 4.9% discount to Tuesday’s closing price. The sale brings in roughly $175 million in gross proceeds.…
-
TSMC posts nearly 34% jump in August sales amid AI chip boom
Taiwan Semiconductor Manufacturing Corp, or TMSC, (NYSE:TSM) reported on Wednesday that its August revenue surged almost 34%, driven by soaring demand for AI-related chips, reinforcing its position as the world’s largest contract semiconductor manufacturer. The company said August sales reached T$335.77 billion ($11.09 billion), a 33.8% increase year-on-year. For the January-August period, revenue climbed 37.1%…
-
Fifth Third Bancorp shares drop after potential $200M fraud uncovered
Shares of Fifth Third Bancorp (NASDAQ:FITB) fell 2.7% in after-hours trading on Tuesday after the Cincinnati-based bank revealed it may face losses of up to $200 million due to alleged fraud involving a commercial borrower. The lender reported it identified “alleged external fraudulent activity” linked to an asset-backed finance loan with an outstanding balance near…